Pyrocam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pyrocam

Property Description
Active Ingredient Piroxicam
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic compound (oxicam derivative)
Common Use Relief of pain and inflammation
Forms Capsule, Tablet, Solution for Injection, Topical Gel

Pyrocam is the designation for a medicinal product containing the active ingredient Piroxicam, a powerful synthetic compound that belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. Piroxicam is specifically classified as an oxicam derivative, which are enolic acid compounds structurally distinct from most other common NSAIDs. Piroxicam, like other NSAIDs, is used to manage pain and inflammatory conditions, a property supported by its chemical structure. Piroxicam is often recognized for its longer half-life compared to standard NSAIDs, a characteristic considered when assessing treatment duration.

What is the General Therapeutic Purpose of Pyrocam?

The general therapeutic purpose of Pyrocam is its tri-modal action: it functions as an anti-inflammatory agent, an analgesic (pain reliever), and an antipyretic agent (fever reducer). This comprehensive functionality aims to alleviate the cluster of symptoms associated with inflammatory states, such as stiffness, discomfort, and elevated temperature. For instance, the drug is commonly used to address the pain and swelling accompanying a condition like a sprain or muscle strain. Piroxicam achieves its effects by acting as a cyclooxygenase (COX) inhibitor, which prevents the production of pro-inflammatory prostaglandins—key mediators of pain and swelling. Piroxicam has clinically recognized efficacy in managing acute and chronic pain states, appearing effective for reducing pain and inflammation in the short and long term.

What Forms of Piroxicam Are Available?

The active substance Piroxicam is available as a single-ingredient product in multiple high-level pharmaceutical forms to accommodate different administration needs. These include oral presentations, such as capsules and tablets, and solutions for intramuscular (IM) injection. A distinguishing feature of Piroxicam is the frequent availability of a topical gel formulation, allowing the active ingredient to be applied directly to a localized area of inflammation, avoiding systemic absorption for minor conditions. The composition consists solely of the active substance Piroxicam combined with suitable pharmaceutical bases or vehicles appropriate for the intended delivery format.

Regulatory References

  1. Piroxicam - NCBI Bookshelf - NIH

What side effects are possible with Pyrocam?

Possible side effects and safety information

The official safety profile for Pyrocam, which contains the NSAID Piroxicam, is structured around mandated regulatory classifications of adverse reactions, grouping them by frequency and the physiological systems affected. These classifications ensure that possible side effects are communicated in a neutral, medically grounded manner.


Adverse Reaction Scope

Component Description
Common Effects Reactions officially classified as Common (ge 1/100 to <1/10) include gastrointestinal issues such as nausea, constipation, abdominal pain, and diarrhea, along with nervous system effects like headache and dizziness, and fluid retention (oedema).
System-Organ Classes Adverse reactions are documented across several body systems, most prominently Gastrointestinal Disorders, Nervous System Disorders, Cardiac/Vascular Disorders, and Renal and Urinary Disorders.
Serious Adverse Reactions Regulatory documents carry mandatory warnings for rare but critical events, including the potential for serious gastrointestinal bleeding, ulceration, and perforation, as well as an increased risk of cardiovascular thrombotic events (myocardial infarction and stroke). Severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS), are also noted.

Safety Patterns and Restrictions

Official labeling defines specific safety constraints. For instance, the medicine is contraindicated for pain management following Coronary Artery Bypass Graft (CABG) surgery and in patients with active peptic ulceration or bleeding. Risk patterns are often tied to exposure: the risk of gastrointestinal side effects is documented to increase with higher doses (above 20 mg per day) and the cardiovascular risk may increase with duration of use.

Population-Specific Notes: Safety considerations are heightened for older adults, who have an officially documented increased risk of serious gastrointestinal complications. Additionally, use in the third trimester of pregnancy is contraindicated due to potential fetal vascular risk.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The official regulatory profile for Piroxicam overdose details a spectrum of documented signs, ranging from general discomfort to severe, life-threatening systemic events. These manifestations must be recognized as triggers for seeking immediate medical assistance.

System Affected Documented Overdose Manifestations
Gastrointestinal Nausea, vomiting, stomach pain, bloody or black/tarry stools, or vomiting material resembling coffee grounds. Severe outcomes include ulceration, perforation, and major GI bleeding, which can be fatal.
Neurological Symptoms may include drowsiness, severe headache, dizziness, agitation, and confusion. Life-threatening manifestations can involve convulsions (seizures) and decreased level of consciousness leading to coma.
Renal/Systemic Ringing in the ears (tinnitus), blurred vision, low blood pressure (shock), and signs of kidney distress such as little to no urine production.

When to Seek Immediate Medical Help

Official guidance mandates that immediate medical attention be sought for any suspected overdose. Emergency services or the Poison Help line must be contacted without delay, particularly if severe signs are observed. The management of overdose is defined as symptomatic and supportive, focusing on treating the clinical manifestations and monitoring the patient’s condition. Authorities confirm that no specific antidote is known for Piroxicam. Due to the inherent risk of severe GI events, particularly in the elderly population, continuous monitoring and observation in a hospital setting may be required.

Therapeutic Uses of Pyrocam

The therapeutic utility of Piroxicam is generally directed toward symptomatic relief across domains where pain, swelling, and physical restriction are symptoms related to inflammatory or irritative states. The medication is indicated for the relief of the signs and symptoms associated with the primary inflammatory conditions of the joints.

Comprehensive Symptom Management

Piroxicam is commonly used to help with distressing manifestations of chronic conditions, including rheumatoid arthritis and osteoarthritis. It is also applied when supportive symptomatic assistance is needed for acute musculoskeletal issues, such as sprains, strains, and episodes of inflammatory arthritis like acute gout. Furthermore, the medication is relevant for easing pronounced symptoms like fever and the acute, localized pain of primary dysmenorrhea. This supports general well-being during symptomatic phases.

“The primary goal is providing support that helps ease the overall symptom burden when pain and inflammation interfere with daily functioning.”

Therapeutic Benefits and Quick Fact

The medication may assist with managing the cluster of joint pain, stiffness, and swelling that interfere with daily functioning. Applied in clinical settings that involve acute or unstable symptom patterns, it helps patients cope more steadily with difficult episodes by easing distress.


Quick Fact: Relief for Inflammatory Discomfort

Piroxicam is generally applied across conditions characterized by periods of heightened symptoms related to inflammatory or irritative states, contributing to easing the overall symptom load.

Regulatory References

  1. FDA DailyMed label overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Pyrocam — official regulatory information

Note: Pyrocam is a veterinary medicine (meloxicam) approved for use in specific animal species: pigs, cattle, and horses.


Populations for whom use is contraindicated

The medicine must not be used in any target species that is suffering from impaired hepatic, cardiac, or renal function, haemorrhagic disorders, or has evidence of ulcerogenic gastrointestinal lesions. Use is also prohibited in animals with known hypersensitivity to the active substance or any excipients.

Age and Condition Restrictions

  • Age: Use is not established in horses less than six weeks of age, or in cattle less than one week of age (for diarrhoea treatment).
  • Physiological State: Use should be avoided in very severely dehydrated, hypovolaemic, or hypotensive animals due to the potential risk of renal toxicity.
  • Pregnancy/Lactation: Use is contraindicated in pregnant or lactating mares. However, it can be used during pregnancy and lactation in cattle and pigs.

Eligibility-Related Restrictions

The product must not be administered concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs (NSAIDs), or with anticoagulant agents.

What should I know about interactions with other medicines?

The official regulatory profile for Pyrocam (Piroxicam) establishes several classifications of interaction patterns with other medicines and products.

Formal contraindications prohibit the concurrent use of Pyrocam with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, and with Acetylsalicylic Acid at analgesic doses. The co-administration with anticoagulants such as Warfarin is also formally prohibited due to the significantly increased risk of serious bleeding events. Furthermore, the use of Pyrocam is restricted in the setting of peri-operative pain for coronary artery bypass graft (CABG) surgery.

A second domain involves altered plasma exposure. Piroxicam may increase the serum concentrations of drugs like Lithium and Digoxin by reducing their renal clearance. Additionally, Piroxicam's metabolism is primarily mediated by the CYP2C9 enzyme, meaning individuals known as poor metabolizers of CYP2C9 substrates may have abnormally high systemic levels.

Pharmacodynamic interactions include the diminished efficacy of antihypertensive agents (ACE inhibitors, ARBs) and diuretics. The risk of gastrointestinal complications is additively increased when Pyrocam is co-administered with oral corticosteroids, SSRIs, or consumed with alcohol. Specific population caution is noted for elderly and volume-depleted patients taking antihypertensives, where the combination may result in a formal risk of renal function deterioration.

Mechanism of Action

How Pyrocam Works

The mechanism of Piroxicam (Pyrocam) is centered on the inhibition of key enzymes in the eicosanoid pathway, leading to a cascade of physiological adjustments that shape its overall effect profile.


Inhibition of Prostaglandin Synthesis at the Core

Piroxicam acts as a non-selective, reversible inhibitor of the Cyclooxygenase ( COX) enzymes, targeting both COX-1 and COX-2. By blocking these enzymes, the drug prevents the conversion of arachidonic acid into prostaglandin and thromboxane precursors, which are signaling lipids that mediate cellular and systemic physiological responses. This molecular blockade results in the modulation of signaling within the affected pathways.


Modulation of Peripheral Nociceptive and Central Thermoregulatory Signaling

The suppression of prostaglandin synthesis directly influences two physiological systems: the peripheral nervous system and the central hypothalamic system. In the periphery, reduced PGE2 concentration limits the sensitization of pain-sensing neurons. Centrally, the mechanism engages the hypothalamus to facilitate the restoration of the thermal set-point.


Mechanism Constraint via Non-Selectivity

The drug's mechanism is constrained by its lack of specificity, as it simultaneously inhibits the COX-1 enzyme responsible for constitutive 'housekeeping' functions, such as the production of mediators that regulate the gastrointestinal mucosa. This non-selective action shapes the mechanism's physiological profile by suppressing the synthesis of both inducible and constitutive prostaglandin mediators.

Dosage and Administration Information

Pyrocam (Piroxicam) administration is defined by specific guidelines regarding dosage route, frequency, and duration, serving as the basis for its proper clinical use.

The medicine is available in various forms to accommodate administration needs, including oral (capsules, tablets), topical (gel), and a solution for intramuscular (IM) injection.

The standard adult regimen for chronic conditions like rheumatoid and osteoarthritis is 20 mg taken once daily. The daily dose may also be taken in divided portions of 10 mg twice daily. For acute, severe conditions such as acute gout, a higher initial daily dose of 40 mg may be utilized for a brief period of four to six days before discontinuing or reducing the dose.

Contextual and Duration Instructions

Oral dosage forms must be consumed with or immediately after food or water to align with proper usage guidelines. The overarching instruction governing all use is the application of the lowest effective dose for the shortest possible duration.

For long-term management, the full therapeutic effect should be assessed only after two weeks of continuous therapy, as steady-state plasma concentrations take time to establish. Dosage adjustments are specified for certain populations; for instance, administration to older adults requires individual assessment and the use of the absolute minimum dose. The product is not recommended for children under 12 years for most general indications.

Recent Clinical Evidence

Pyrocam: Recent Clinical Evidence

Research on the compound Pyrocam (pyronaridine-artesunate) has explored its potential applications beyond its approved uses, particularly in large-scale infectious disease management. Studies focus on evaluating the safety profile and whether the compound is associated with improved clinical outcomes in specific patient groups.


Efficacy and Safety Trials

Phase 2/3 trials have investigated the use of Pyrocam in participants diagnosed with certain viral infections, including mild to moderate COVID-19. These multi-center, randomized, double-blind, placebo-controlled studies aimed to determine the efficacy of the oral compound as a treatment.

Key endpoints evaluated in these trials included:

  • Percentage of subjects who required hospitalization or death due to infection until a specified follow-up day.
  • Time required to achieve sustained clinical recovery (discharge) in hospitalized subjects.
  • Changes in the severity of clinical symptoms over the study period, measured using clinical progression scales.

Studies also closely monitored potential adverse events, particularly those related to cardiac and hepatic function, as trial exclusion criteria often involved participants with severe hepatic impairment or pre-existing cardiac conditions like corrected QT interval prolongation.


Combination Research

Research protocols have also examined Pyrocam's use in combination with standard treatments. The hypothesis is that combining the compound with existing care may influence the clinical progression of the disease. While the core studies focus on the compound as a standalone treatment, ongoing observational studies continue to gather real-world data on its tolerability and outcomes when administered alongside other established therapeutics.

Frequently Asked Questions (FAQ)

Common questions about Pyrocam (FAQ)

Q: What are the approved medical conditions or uses for Pyrocam?

A: According to the official prescribing information, the active ingredient Piroxicam is formally approved for the relief of the signs and symptoms associated with rheumatoid arthritis and osteoarthritis. This means the drug is regulated for use in managing the pain and inflammation related to these specific chronic joint conditions.

Q: Is there a generic version of Pyrocam available?

A: Yes. Pyrocam is a brand name for the active ingredient Piroxicam. Piroxicam is the generic name, and it is available in generic form as capsules and tablets marketed by various manufacturers, as confirmed by regulatory product labeling.

Q: What is the difference between Pyrocam and other common NSAIDs?

A: Official pharmacological documents describe Piroxicam as an oxicam derivative, which is a unique chemical classification. A key characteristic is its relatively long elimination half-life (the time it takes for half of the drug to be cleared from the body), which may influence how often the medication is taken compared to shorter-acting medicines in its class.

Q: Does Pyrocam have a 'Black Box Warning' from the FDA or similar agency?

A: Yes, regulatory documents issued by the FDA include a BOXED WARNING for the drug. This warning emphasizes the potential for serious cardiovascular thrombotic events (such as heart attack and stroke) and serious gastrointestinal adverse events (such as bleeding and ulceration) that may occur with use.

Q: What are the signs of potential stomach or intestinal bleeding from Pyrocam?

A: Signs that may indicate a serious bleeding issue include passing bloody or black/tarry stools, or vomiting material that resembles coffee grounds. Regulatory agencies document that patients should be aware of these potential symptoms.

Q: What are the risks of using Pyrocam for someone who already has high blood pressure?

A: Official warnings state that Pyrocam can potentially lead to the onset of new high blood pressure, or it may worsen existing hypertension. For this reason, official labeling notes that blood pressure requires close monitoring during treatment.

Q: Is ringing in the ears (tinnitus) a known side effect of Pyrocam?

A: Tinnitus, or a persistent ringing in the ears, is described in official documents as a possible adverse reaction that has been reported. While it is not classified as one of the most common side effects, regulatory data acknowledges its potential occurrence.

Q: Can Pyrocam affect my liver function or cause jaundice?

A: Yes, regulatory documents indicate that serious liver reactions have been reported in association with the drug's use. These reactions include jaundice (yellowing of the skin or eyes) and, in rare instances, cases of fatal fulminant hepatitis (severe liver inflammation).

Q: What signs indicate a severe allergic reaction to Pyrocam?

A: Signs of a serious allergic or hypersensitivity reaction may include the rapid development of hives, swelling of the face, tongue, or throat, or difficulty breathing. Should these signs occur, they are documented in regulatory materials as serious events.

Q: Does Pyrocam interact with any common over-the-counter pain relievers like paracetamol/acetaminophen?

A: While regulatory documents do not specifically list acetaminophen (paracetamol) as an interaction, the use of Piroxicam is formally contraindicated (prohibited) with any other Non-Steroidal Anti-inflammatory Drug (NSAID) or aspirin at analgesic doses. This is due to an increased risk of side effects.

Q: Are there any specific foods or supplements that should be avoided when taking Pyrocam?

A: Official patient instructions recommend that oral forms of the medicine be taken with food or water. Beyond alcohol, which increases gastrointestinal risk, no specific foods or dietary supplements are formally restricted in the regulatory labeling.

Q: Who is generally considered ineligible or restricted from using Pyrocam?

A: Official regulatory documents state that the drug is contraindicated (should not be used) in patients with severe heart failure, severe hepatic (liver) or renal (kidney) impairment, or a history of active gastrointestinal ulceration or bleeding. These are formal restrictions based on safety profiles.

Q: What is the risk of taking Pyrocam for someone who has had a previous heart attack or stroke?

A: Regulatory warnings state that use of the drug is generally advised to be avoided in patients who have recently experienced a heart attack (myocardial infarction). This caution is due to the potential for increased cardiovascular risks.

Q: Does Pyrocam have any known effect on fertility or ovulation?

A: Official regulatory information notes that based on its mechanism of action as an NSAID, the use of Piroxicam may impair female fertility. For this reason, it is generally not recommended for women who are actively attempting to conceive.

Q: How quickly does Pyrocam start working to provide relief?

A: Official clinical pharmacology documents report that peak plasma concentrations of the drug are generally achieved within three to five hours following oral administration. This measurement indicates the time it takes for the maximum amount of the drug to be available in the bloodstream.

Q: What is the typical half-life of Pyrocam in the body?

A: The elimination half-life of Piroxicam is officially reported in pharmacological documents to be approximately 50 hours. The half-life is the amount of time required for the concentration of the drug in the body to be reduced by half.

Q: Is Pyrocam known to cause chemical dependence or have addictive properties?

A: Regulatory analysis confirms that Piroxicam is not classified as a controlled substance by major government bodies. This indicates that the medication is not associated with abuse potential or the risk of chemical dependence.

Q: Should a patient with aspirin-sensitive asthma avoid taking Pyrocam?

A: Yes, the drug is formally contraindicated in patients who have a known history of developing asthma, hives (urticaria), or allergic-type reactions after taking aspirin or any other non-steroidal anti-inflammatory drugs (NSAIDs). This is a required safety measure.

Q: Does Pyrocam affect the results of any lab tests?

A: Official documents do not list specific lab test interference. However, adverse effects have been reported that include transient (temporary) increases in liver enzymes and BUN/creatinine levels, which are markers monitored during certain blood tests.

How should Pyrocam be stored and disposed of?

How to Store and Dispose of Pyrocam (Piroxicam) Capsules

Piroxicam capsules must be stored at Controlled Room Temperature, which regulatory labeling defines as between 15 C and 30 C (59 F and 86 F). Storage above 30 C is not permitted. The product must be protected from light and moisture, and the container must be kept tightly closed to maintain product stability.

Official Disposal

The preferred method for discarding unused or expired Pyrocam is through an official community drug take-back program. If a take-back program is unavailable, the FDA advises removing the medicine from its container, mixing it with an undesirable substance like coffee grounds or dirt, and placing the mixture into a sealed bag or container before disposal in the household trash. Identifying personal information must be removed from the original prescription label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pyrocam found in:

A-Z Index: